What changed in the 2024 vitamin D guideline?
In June 2024, the Endocrine Society published its clinical practice guideline, “Vitamin D for the Prevention of Disease,” with the full paper appearing in the Society's journal in August. It replaced the 2011 guideline but asked a narrower question: can vitamin D use or measurement of 25-hydroxyvitamin D (25[OH]D) prevent disease in people who do not already have an established indication for treatment or testing? Its most practical conclusion was that a healthy adult does not need routine screening merely for reassurance or to pursue an ideal number [1, 2, 4].
This does not mean vitamin D became unimportant or testing was banned. The change separates two pathways: population screening in a healthy person with no clinical reason, and targeted assessment in someone whose disease, signs or treatment could change a medical decision. The guideline focused on the first pathway and expressly does not apply to people with an established indication for 25(OH)D testing or vitamin D treatment [1, 2, 6].
Every recommendation uses “suggest” rather than a strong “recommend.” In GRADE terminology these are conditional recommendations requiring contextual application, not universal commands. The supporting systematic review found no trials assessing the benefits and harms of 25(OH)D screening itself, and no single level shown to deliver a defined prevention benefit for every healthy person. The update did not identify a magic target; it concluded that available evidence does not justify testing everyone without a reason [1, 3].
Vitamin D testing in healthy adults: why “routine” matters
The test discussed here is 25(OH)D, the usual laboratory marker of vitamin D status. The Endocrine Society suggests against routine testing in healthy adults younger than 50, those aged 50 to 74, and those aged 75 or older. Even in healthy pregnancy, obesity and dark complexion, the panel found no outcome-trial evidence showing that routine screening improves health or identifies a useful prevention target [1, 2].
The word “routine” matters. It describes a person without directed symptoms, a disorder affecting bone, calcium or absorption, a medicine altering vitamin D metabolism, or a treatment plan requiring monitoring. Ordering the test annually in a general panel, or repeating it because a laboratory number is below a value seen online, differs from ordering it to answer a defined medical question. A test has value when its result may change a decision [1, 8, 9].
This partly aligns with the US Preventive Services Task Force (USPSTF), which found insufficient evidence to determine the balance of benefits and harms of screening nonpregnant adults without signs, symptoms or conditions for which treatment is recommended. The formulations are not identical: the 2024 guideline “suggests against” routine testing, while the USPSTF issued an insufficient-evidence statement. Their shared message is that a low number found through broad screening does not by itself prove that screening improves health [1, 8].
If fatigue is your only concern, a result does not automatically explain it. Our guide, I am tired all the time. Should I take vitamin D without a test?, explains fatigue assessment; this update focuses on population screening [7, 8].
Which groups were offered empiric vitamin D without targeting a level?
The guideline suggests empiric vitamin D for four groups: children and adolescents aged 1 to 18 to prevent nutritional rickets and potentially reduce respiratory infections; adults aged 75 or older because of a possible mortality benefit; healthy pregnant people because of potential improvements in selected pregnancy and birth outcomes; and adults with high-risk prediabetes, alongside lifestyle modification, because of possible reduced progression to diabetes [1, 2, 5].
“Empiric” does not mean random treatment or invite anyone to choose a concentration or injection independently. It means that prevention in these groups need not begin with a 25(OH)D test or target a laboratory number. Vitamin D may come from fortified foods, a vitamin preparation, or an appropriate supplement selected according to age, clinical context and local guidance. The guideline could not identify one optimal dose because trial doses, schedules and background supplement use varied [1, 3, 6].
Evidence certainty differed: it was low for respiratory infections in children and several pregnancy outcomes, moderate for progression to diabetes in high-risk prediabetes, while the review found a very small mortality reduction in adults older than 75 with higher-certainty evidence. We should retain “potential benefit” rather than turn a conditional suggestion into a promise [1, 3].
For a healthy, nonpregnant adult aged 19 to 74, the guideline suggests against supplementation above the dietary reference intake merely to prevent disease. A published correction clarified “beyond the recommended Dietary Reference Intake” so the statement is not misread as advice to avoid vitamin D in food or ordinary recommended intake [1, 4].
Who may still need testing for a clinical reason?
Advice against routine screening in healthy people does not mean nobody needs a test. The guideline excludes anyone with an established indication for treatment or testing; its direct example is hypocalcaemia. The patient summary also explains that it does not cover intestinal disease or bariatric surgery that may lower vitamin D status, or conditions requiring careful vitamin D management, such as osteoporosis and blood-calcium disorders [1, 2, 6].
A clinician may test when osteomalacia or another metabolic bone disorder is suspected, during osteoporosis assessment and treatment, or after a low-trauma fracture as part of broader bone evaluation. Testing may answer a question in malabsorption caused by intestinal disease or altered anatomy, unusual renal loss, or liver or kidney disease affecting vitamin D handling. Some medicines reduce absorption, accelerate vitamin D breakdown, or make supplementation require monitoring. These are examples of clinical questions, not an automatic list requiring everyone to test on the same schedule [7, 9, 11].
Bone symptoms, clear muscle weakness, abnormal calcium, or clinician-directed treatment for confirmed deficiency can change the question from “Should we screen a healthy person?” to “How should we evaluate this condition?” The clinician then interprets 25(OH)D with history, examination, calcium, kidney function and sometimes other markers; the number alone does not diagnose the cause or determine the whole plan [7, 10].
Obesity and dark complexion are associated with lower 25(OH)D in observational studies, but the guideline suggests against routine screening based on either factor alone in an otherwise healthy person. This does not cancel testing for bone disease, malabsorption or another independent indication [1, 2].
What this means for you
If you are a healthy adult with no clear reason for testing, this update means a vitamin D test should not be automatic every year. Ask: what clinical question will it answer, and would a lower or higher result change a decision? You may not need the test, or the discussion may uncover a specific reason that makes it useful [1, 8, 9].
If an old result is labelled “low,” do not interpret it without its date, unit, reason for testing and the supplements used at the time. Variation in assays and thresholds, plus the absence of one proven disease-prevention target, makes comparison across laboratories or pursuit of a social-media number unreliable. Conversely, do not ignore a result ordered during bone, calcium or malabsorption assessment; that lies outside broad screening [1, 7, 10].
If you already take a supplement, do not start, stop or change it because of a guideline headline. Gather every vitamin D source: a stand-alone supplement, multivitamin, and calcium product containing vitamin D. Photograph labels and record duration because duplicated ingredients are easy to miss. If a clinician prescribed treatment for a defined condition, the update does not cancel it; review its reason and monitoring purpose with the prescriber [6, 7].
Most importantly, “no routine test” does not mean “take a large amount without testing.” The guideline did not establish one optimal dose for empiric prevention, and in people aged 50 or older who require treatment it preferred lower daily administration over large intermittent doses. This article gives no doses; selection depends on age, pregnancy, diet, disease and medicines [1, 3].
Children, pregnancy and prediabetes: different decisions
In children and adolescents, a suggestion for empiric prevention does not turn blood testing into a routine step or turn prevention into treatment for rickets or confirmed deficiency. Age, feeding, fortified foods and growth require different considerations, while bone signs or malabsorption change the pathway. Our guide, Vitamin D in Children: When to Test, covers those details and warning signs rather than repeating them here [1, 2].
In healthy pregnancy, the guideline suggests empiric vitamin D because of possible improvements in selected outcomes, while suggesting against routine 25(OH)D testing because trials have not established a pregnancy-outcome-specific level. This is not permission to select a product or concentration without the pregnancy-care team; prenatal vitamins may already contain vitamin D, and some diseases or calcium abnormalities move the case outside general prevention [1, 6].
The prediabetes suggestion mainly reflects adults with high-risk prediabetes defined by specific glycaemic criteria in trials, and is additional to lifestyle modification rather than a substitute. Prediabetes cannot be diagnosed from a general symptom or vitamin D test, and supplementation is not guaranteed diabetes prevention. The review described a possible benefit with moderate-certainty evidence, while the glucose plan depends on glucose measures and the whole clinical picture [1, 3].
In adults older than 75, the suggestion rests on a very small possible mortality reduction across studies, not an individual promise or a requirement to reach a particular level. The guideline still suggests against routine testing in this group without another indication [1, 3].
What to prepare for an internal-medicine review
If it is unclear whether testing is indicated, prepare a defined question instead of requesting a broad panel. Record symptoms and duration, bone pain, muscle weakness or fractures, intestinal disease or bariatric surgery, and liver, kidney, parathyroid or osteoporosis history. Bring dated prior 25(OH)D, calcium and kidney-function results with units; do not compare a unitless number with a different reference system [6, 7, 9].
Bring a complete medicine and supplement list and package photographs. Mention antiseizure medicines, steroids, medicines reducing fat absorption, and any treatment your clinician says affects vitamin D or calcium. Do not stop a prescribed medicine; the clinician weighs its benefit against any separate need for measurement or monitoring [7, 9].
The visit is not only about asking, “What is the number?” The clinician decides whether this is routine screening in a healthy person or targeted testing because of disease or medicine, and whether the result would change a plan. Injections or megadoses without diagnosis and monitoring are not a safe shortcut; excess vitamin D can raise calcium and damage the kidneys and other tissues [7, 10].
For individual assessment, you can book an internal-medicine consultation with the medical team at La Rose in Maadi; Dr Mohab Ashraf is available on Saturday. There is no online internal-medicine service. Bring your results, packages and medicine list. For severe confusion, persistent vomiting with excessive thirst and urination, profound weakness, altered consciousness or suspected large ingestion, seek urgent care rather than waiting [7].
